Referred to the House Committee on Energy and Commerce.
The bill amends the Affordable Care Act to create an annual out-of-pocket limit on cost-sharing for prescription drugs for health plans with plan years beginning on or after January 1, 2027. For 2027 the limit is $2,000 for self-only coverage and, for other coverage, twice the self-only amount; thereafter the limits are indexed annually using the statute’s premium adjustment percentage and rounded to the nearest lower multiple of $50.
Scope and coverage: liberals assume benefits for patients; conservatives emphasize likely exemptions for ERISA/self-funded employer plans and object to federal mandates.
Relative to its intended legislative type, this bill is a straightforward statutory amendment that sets a specified annual dollar limit on prescription drug cost-sharing beginning in 2027, with indexing and basic family/self-only rules; it integrates into named ACA and PHSA provisions but leaves several operational and fiscal details unaddressed.
The bill amends the Affordable Care Act to create an annual out-of-pocket limit on cost-sharing for prescription drugs for health plans with plan years beginning on or after January 1, 2027.
For 2027 the limit is $2,000 for self-only coverage and, for other coverage, twice the self-only amount; thereafter the limits are indexed annually using the statute’s premium adjustment percentage and rounded to the nearest lower multiple of $50.
The bill adds conforming edits to related ACA and Public Health Service Act language to reflect the new prescription drug cost-sharing limitation.
Content-wise the bill is a straightforward, administrable change that addresses a popular problem (high out-of-pocket drug costs) and therefore has plausible political appeal. However, it mandates insurer benefit design changes with likely downstream premium and subsidy effects and would draw organized opposition from industry stakeholders. Without offsets, consensus procedures, or inclusion in a larger vehicle with political momentum, the bill faces meaningful obstacles—especially in the Senate—so its chance of becoming law based on text alone is moderate but uncertain.
Relative to its intended legislative type, this bill is a straightforward statutory amendment that sets a specified annual dollar limit on prescription drug cost-sharing beginning in 2027, with indexing and basic family/self-only rules; it integrates into named ACA and PHSA provisions but leaves several operational and fiscal details unaddressed.
Scope and coverage: liberals assume benefits for patients; conservatives emphasize likely exemptions for ERISA/self-funded employer plans and object to federal mandates.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and coverage: liberals assume benefits for patients; conservatives emphasize likely exemptions for ERISA/self-funded employer plans and object to federal mandates.
This persona will generally view the bill positively as a concrete step to reduce out-of-pocket drug costs and improve access to medicines for people on ACA plans.
They will see the $2,000 cap in 2027 (and family cap) as a meaningful protection against catastrophic prescription drug spending and likely applaud the indexing to maintain value over time.
They will note remaining uncertainties — for example whether employer self-funded plans are covered — but see the bill as aligned with goals to make health care more affordable and equitable.
A centrist view will see the bill as a targeted affordability measure with clear benefits for people facing high drug costs, but will be cautious about unintended consequences for premiums and market stability.
They will want empirical estimates (CBO/HHS) of fiscal and premium impacts, clarity on which plans are covered, and reasonable guardrails to prevent cost-shifting.
If the bill comes with offsetting provisions, implementation guidance, and evidence that premium impacts are small, a centrist would be moderately supportive.
This persona will likely oppose the bill as an expansion of federal mandates on private health coverage that could increase costs, distort markets, and represent federal overreach.
They will emphasize that capping patient cost-sharing can remove price signals, leading to higher overall costs and potential premium increases.
They will also highlight uncertainty about how the policy would be paid for and whether it would apply to self-funded employer plans (preferring that it not).
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content-wise the bill is a straightforward, administrable change that addresses a popular problem (high out-of-pocket drug costs) and therefore has plausible political appeal. However, it mandates insurer benefit design changes with likely downstream premium and subsidy effects and would draw organized opposition from industry stakeholders. Without offsets, consensus procedures, or inclusion in a larger vehicle with political momentum, the bill faces meaningful obstacles—especially in the Senate—so its chance of becoming law based on text alone is moderate but uncertain.
The bill has not accumulated any surfaced votes yet.
Scope and coverage: liberals assume benefits for patients; conservatives emphasize likely exemptions for ERISA/self-funded employer plans a…
Content-wise the bill is a straightforward, administrable change that addresses a popular problem (high out-of-pocket drug costs) and there…
Relative to its intended legislative type, this bill is a straightforward statutory amendment that sets a specified annual dollar limit on prescription drug cost-sharing beginning in 2027, with indexing and basic family…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.